Circulating Micro-RNA As a Predictive Biomarker for Radiation Response in Pancreas Cancer

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Nov 15

PMID 39546102

Authors

Mark S Etherington

Giorgos C Karakousis

Affiliations

Soon will be listed here.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Evans D . What Makes a Pancreatic Cancer Resectable?. Am Soc Clin Oncol Educ Book. 2018; 38:300-305. DOI: 10.1200/EDBK_200861. View

Versteijne E, van Dam J, Suker M, Janssen Q, Groothuis K, Akkermans-Vogelaar J . Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022; 40(11):1220-1230. DOI: 10.1200/JCO.21.02233. View

Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B . Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022; 8(9):1263-1270. PMC: 9284408. DOI: 10.1001/jamaoncol.2022.2319. View

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

Croce C . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10(10):704-14. PMC: 3467096. DOI: 10.1038/nrg2634. View

Metcalf G . MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene. 2024; 43(28):2135-2142. PMC: 11226400. DOI: 10.1038/s41388-024-03076-3. View

Ding Z, Wu H, Zhang J, Huang G, Ji D . MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles. Tumour Biol. 2014; 35(9):8837-48. DOI: 10.1007/s13277-014-2133-4. View

Yang I, Yip K, Chang Y, Chen Y, Huang C, Tsai H . MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review. Cancers (Basel). 2023; 15(5). PMC: 10000071. DOI: 10.3390/cancers15051358. View

10.

Lang C, Lloyd M, Alyacoubi S, Rahman S, Pickering O, Underwood T . The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer. Cancers (Basel). 2022; 14(5). PMC: 8909542. DOI: 10.3390/cancers14051171. View

11.

Hummel R, Hussey D, Haier J . MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2009; 46(2):298-311. DOI: 10.1016/j.ejca.2009.10.027. View

12.

Tanaka Y, Higami S, Ishii T, Shiki Y, Ueda Y, Kimura T . Adjuvant Chemotherapy versus Concurrent Chemoradiotherapy for Surgically Treated T1b Uterine Cervical Cancer: A Propensity Score Matched Analysis of the JSOG Nationwide Data. Ann Surg Oncol. 2024; 32(3):2206-2212. DOI: 10.1245/s10434-024-16638-2. View

13.

Liu N, Wang A, Xue M, Zhu X, Liu Y, Chen M . FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer. Cell Death Discov. 2024; 10(1):172. PMC: 11009302. DOI: 10.1038/s41420-024-01936-1. View

14.

Qiao L, Chen Y, Liang N, Xie J, Deng G, Chen F . Targeting Epithelial-to-Mesenchymal Transition in Radioresistance: Crosslinked Mechanisms and Strategies. Front Oncol. 2022; 12:775238. PMC: 8888452. DOI: 10.3389/fonc.2022.775238. View

15.

Jan I, Chang H . Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy. Radiat Oncol. 2023; 18(1):137. PMC: 10439654. DOI: 10.1186/s13014-023-02328-y. View